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mTOR complex 1 (mTORC1; mammalian target of ra-
pamycin [mTOR] in complex with raptor) is a key
regulator of protein synthesis and cell growth in
response to nutrient amino acids. Here we report
that inositol polyphosphate multikinase (IPMK),
which possesses both inositol phosphate kinase
and lipid kinase activities, regulates amino acid
signaling to mTORC1. This regulation is independent
of IPMK’s catalytic function, instead reflecting its
binding with mTOR and raptor, which maintains the
mTOR-raptor association. Thus, IPMK appears to
be a physiologic mTOR cofactor, serving as a deter-
minant of mTORC1 stability and amino acid-induced
mTOR signaling. Substances that block IPMK-
mTORC1 binding may afford therapeutic benefit in
nutrient amino acid-regulated conditions such as
obesity and diabetes.
INTRODUCTION
Inositol phosphates (IPs) such as diphosphoinositol penta-
kisphosphate (IP7) regulate diverse processes including endo-
cytosis (Saiardi et al., 2002), chemotactic signaling (Luo et al.,
2003), and maintenance of telomere length (Saiardi et al.,
2005). In the cloning of IP6 kinases (IP6Ks) responsible for gener-
ating IP7, we identified inositol polyphosphate multikinase
(IPMK) (Saiardi et al., 1999). In contrast to other members of
the IP6K family, IPMK does not form IP7 but instead synthesizes
Ins(1,4,5,6)P4 and subsequently Ins(1,3,4,5,6)P5 by adding
a phosphate at the three or six positions (Saiardi et al., 1999;
Odom et al., 2000). IPMK also displays lipid kinase activity,
phosphorylating phosphatidylinositol-4,5-bisphosphate (PIP2)
to generate phosphatidylinositol-3,4,5-trisphosphate (PIP3)
(Resnick et al., 2005). IPMK was identified in yeast as an essen-
tial gene influencing responses to arginine and hence was
labeled ArgIII or Arg82, and is also known as Ipk2 or yeastCell MIPMK (Be´chet et al., 1970; Saiardi et al., 1999; Odom et al.,
2000). Accordingly, in seeking mammalian functions for IPMK,
we have focused upon amino acid regulation of cell growth via
the mTOR signaling pathway.
mTOR is a protein kinase which mediates the influence of
growth factors as well as nutrient amino acids upon protein
synthesis and growth (Wullschleger et al., 2006). mTOR exists
in two distinct complexes that include several components:
regulatory associated protein of mTOR (raptor) for mTORC1
(Loewith et al., 2002; Kim et al., 2002; Hara et al., 2002) and ra-
pamycin-insensitive companion of mTOR (rictor) for mTOR
complex 2 (mTORC2) (Jacinto et al., 2004; Sarbassov et al.,
2004; Wullschleger et al., 2006). The Rag GTPases, raptor that
is involved in translocating mTOR in a Rag GTPase-mediated
manner (Sancak et al., 2008), and human vacuolar protein sort-
ing 34 (Gulati et al., 2008) have been implicated in amino acid-
mTOR signaling, but how amino acids influence and activate
mTORC1 has not been well delineated.
Here we report that mammalian IPMK mediates the influence
of amino acid stimulation upon mTOR signaling. The action of
IPMK is independent of its catalytic activity. Instead, IPMK stabi-
lizes mTOR-raptor binding in the mTORC1 complex through the
amino-terminal sequence of IPMK, a uniquely mammalian
mTOR-binding site.RESULTS
IPMK Depletion Prevents Amino Acid-Induced mTOR
Signaling
To circumvent the embryonic lethality of conventional IPMK null
mice (Frederick et al., 2005), we generated mouse embryonic
fibroblasts (MEFs) in which IPMK is inducibly depleted (Fig-
ure 1A). Under normal growth conditions, both wild-type and
IPMK-depleted MEFs show a similar level of mTORC1 activity
as monitored by phosphorylation of ribosomal protein S6 kinase
(S6K) (Figure 1A). Withdrawal for 1 hr of serum and amino acids
inactivates mTORC1 (Figure 1A; Hara et al., 1998), while serum
deprivation alone for 1 hr does not affect S6K phosphorylation
in either wild-type or IPMK-depletedMEFs (see Figure S1A avail-
able online).etabolism 13, 215–221, February 2, 2011 ª2011 Elsevier Inc. 215
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Figure 1. IPMK Depletion Diminishes Amino Acid Signaling and mTOR-Raptor Interactions
(A)Wild-type (WT) and IPMK-depleted (KO)MEFswere grown in 10%serum, nutrient-richmedium (control), deprived of serum and amino acids (leucine, arginine,
or total amino acids) for 1 hr. Cells were stimulated by leucine (400 mM), arginine (400 mM), or total amino acids mixture (13) for 10 min.
(B) In vitro mTORC1 activity assay from MEFs.
(C) MEFs were deprived of leucine for 24 hr and stimulated with leucine (400 mM) for 12 hr. Cell size was analyzed from at least 8000 cells per trial (n = 3). Bars
represent mean ± SEM.
(D) IPMK-depleted MEFs stably expressing wild-type or the catalytically inactive, mutant IPMK (K129A) were analyzed as in (A).
(E) mTOR, raptor, and rictor immunoprecipitates were isolated in the presence of DSP, and the amount of indicated mTORC subunits was analyzed. Bars in (A),
(B), and (E) represent mean ± SD (n = 4). **p < 0.01.
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Inositol Polyphosphate Multikinase and mTORWild-type MEFs display marked stimulation of mTORC1 by
arginine and leucine, the two most potent nutrient regulators of
mTOR, as well as by total amino acids (Figure 1A). Depletion of
IPMK reduces mTORC1 signaling in response to all of these
amino acid stimuli by about 60% (Figure 1A and Figure S1B).
Activity of mTOR kinase, assayed in vitro, is also markedly216 Cell Metabolism 13, 215–221, February 2, 2011 ª2011 Elsevier Inreduced in IPMK-depleted MEFs (Figure 1B). Moreover, IPMK
depletion prevents the stimulation by leucine of cell size
(Figure 1C). The diminished signaling does not reflect influences
of IPMK upon amino acid uptake, as intracellular import of argi-
nine, leucine, and a methionine/cysteine mixture is unaltered in
IPMK-depleted MEFs (Figure S1C). In addition, the activity ofc.
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Inositol Polyphosphate Multikinase and mTORmitogen-activated protein kinase, a positive regulator of
mTORC1 (Wullschleger et al., 2006), is unaltered in IPMK-
depleted MEFs (Figure S1D).
To further examine the specificity of IPMK’s role in regulating
nutrient effects on mTORC1, we evaluated influences of oxida-
tive stress elicited by H2O2 or glucose deprivation. Both treat-
ments markedly inhibit mTORC1 signaling to the same extent
in wild-type and IPMK-depleted MEFs, and glucose restoration
reverses mTORC1 activity (Figures S1E and S1F).
IPMK Regulation of mTOR Is Independent of Catalytic
Activity
We wondered whether catalytic activity of IPMK is required for
regulation of mTORC1. Previously, we showed that mutation of
IPMK’s inositol-binding site abolishes its catalytic activity (Re-
snick et al., 2005). In IPMK-depletedMEFs, expression ofmutant
IPMK-K129A restores amino acid-induced mTORC1 signaling
just as well as wild-type IPMK (Figure 1D), establishing that its
regulation of mTOR is independent of catalytic activity. We
were concerned that IPMK-K129A might retain trace amounts
of catalytic activity so that overexpression of IPMK-K129Awould
provide sufficient IPMK products to rescue mTOR signaling
defects. Accordingly, we examined the influence of IPMK-K129A
overexpression on IP generation. IPMK depletion, as expected,
abolishes IP5 and IP6 formation with their generation rescued
by overexpression of wild-type IPMK (Figures S1G–S1I). Overex-
pression of IPMK-K129A in the IPMK-depleted MEFs fails to
restore wild-type levels of IP5 and IP6 (Figure S1J), consistent
with the notion that IPMK’s catalytic activity is not required for
amino acid-induced mTOR signaling. Additionally, we examined
a form of IPMK mutated within the catalytic domain, which also
restores mTORC1 signaling (Figure S2).
IPMK Noncatalytically Stabilizes mTORC1
What noncatalytic functions of IPMK might mediate mTOR acti-
vation?We examined a potential role for IPMK in the stabilization
of mTORC1. To analyze the in vivo status of mTOR complexes,
we isolated mTOR immunoprecipitates prepared from cell
lysates treated with dithiobis(succinimidyl propionate) (DSP),
an established crosslinker widely used for capturing mTORC
subunits in intact cells (Kim et al., 2002; Sarbassov et al.,
2004). Depletion of IPMK markedly reduces mTOR-raptor
binding without influencing the interaction of mTOR with rictor
or mLST8, a subunit required for stabilizing mTORC2 (Guertin
et al., 2006) (Figure 1E). Moreover, the association between
mTOR and the Rag GTPase that binds raptor and mediates
amino acid signaling to mTORC1 is significantly weakened in
IPMK-depleted MEFs, while Rag-raptor binding is unaltered
(Figure S1L). Thus, IPMK appears to act noncatalytically to
selectively stabilize the association between mTOR and raptor
in mTORC1 and thereby mediate amino acid-induced mTOR
signaling.
IPMK Is an mTOR Cofactor
We wondered whether IPMK regulates the stability of mTORC1
by participating in its protein-protein interaction events. To
assess this possibility, we overexpressed GST-tagged human
IPMK (GST-hIPMK) in HEK293T cells and detect endogenous
mTOR in GST-hIPMK pull-down (Figure 2A). RecombinantCell MIPMK and recombinant mTOR interact with each other in trans-
fected HEK293T cells (Figure 2B). Coimmunoprecipitation of
IPMK with either raptor or rictor also reveals that IPMK is
a cofactor for both mTORC1 and mTORC2 (Figure 2C).
Sabatini and associates showed that amino acid deprivation
elicits tight binding betweenmTOR and raptor, which is reversed
by amino acid addition (Kim et al., 2002). Likewise, in our exper-
iments, leucine deprivation enhances binding between mTOR,
raptor, and IPMK, which is reversed by leucine treatment (Fig-
ure S3A). Under crosslinking conditions, leucine deprivation
does not alter IPMK-mTORC1 binding, implying that leucine
regulates the affinity rather than the stoichiometry of the binding
complex (Figure S3B). To examine functional influences of IPMK
on mTORC2 signaling, we monitored insulin-stimulated Akt
Ser473 phosphorylation (Sarbassov et al., 2005), which is
reduced in IPMK-depleted MEFs, as monitored with intact cells
and in vitro (Figures S3C and S3D). The insulin-induced activa-
tion of Akt/mTORC2 by IPMK appears mechanistically distinct
from amino acid-mTORC1 signaling, as it involves IPMK’s cata-
lytic activity (Figure S3E).
Functional interactions of IPMK and mTORC1 imply colocali-
zation. Accordingly, we examined the immunofluorescent
localizations of GFP-tagged hIPMK and endogenous mTOR in
HEK293T cells (Figure S3F). Previous reports showed preferen-
tial nuclear staining of IPMK with modest cytosolic levels (Nalas-
kowski et al., 2002; Fujii and York, 2005; Resnick et al., 2005). In
our present experiments, GFP-hIPMK signals occur with endo-
genous mTOR in a diffusely granular disposition throughout the
cytoplasm with weak nuclear localization, supporting functional
links of the two proteins. Variable results on IPMK’s subcellular
distribution are probably related to differences in overexpression
and cell type.
The Unique Amino Terminus of IPMK Mediates
IPMK-mTOR Binding
In yeast, a role for IPMK as a chaperone for the Arg80/Mcm1
transcription complex is critically dependent upon a polyaspar-
tate domain (Dubois et al., 2000; El Alami et al., 2003), which is
absent in mammalian IPMK (Figure 2D). In contrast, mammalian
IPMK possesses a unique amino terminal extension of 31–60
amino acids that is absent in flies, worms, and yeast. Deletion
of these 60 amino acids in human IPMK markedly reduces
IPMK-mTOR binding (Figure 2E), while the 1–60 fragment of
hIPMK (hIPMK-1-60) itself binds tomTOR, with especially robust
binding to the amino-terminal portion of mTOR (Figure 2F). Puri-
fied hIPMK-1-60 interacts in vitro with immunopurified mTOR,
establishing direct binding between hIPMK-1-60 and mTOR
(Figure 2G). IPMK also binds raptor, but the IPMK-raptor interac-
tion occurs through the C-terminal portions of IPMK, not hIPMK-
1-60 (Figures 2E and 2H).
Human IPMK-1-60 Peptide Disrupts mTORC1 Stability
and Signaling
Because hIPMK-1-60 interacts with the amino terminus of
mTOR, a known raptor-binding site (Kim et al., 2002), we
explored whether hIPMK-1-60 can act in a dominant-negative
fashion. If IPMK is critical for raptor-mTOR binding, might
hIPMK-1-60 interfere with this binding? In GFP-transfected
control HEK293T cells, mTOR-raptor binding is not notablyetabolism 13, 215–221, February 2, 2011 ª2011 Elsevier Inc. 217
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Figure 2. IPMK Is an mTOR-Associated Protein
(A) GST or GST-hIPMK was expressed in HEK293T cells, followed by pull-down and immunoblotting for endogenous mTOR.
(B) GFP or GFP-hIPMK was cotransfected in HEK293T cells with myc-mTOR, and immunoprecipitates were analyzed by immunoblotting.
(C) Lysates from IPMK-depleted MEFs stably expressing wild-type mouse IPMK were immunoprecipitated with indicated antibodies.
(D) The unique sequence found in mammalian IPMK is aligned and indicated with a red box. Yeast IPMK-specific, polyaspartates sequence (Poly-D; green), and
two conserved domains for inositol binding (blue) and kinase activity (yellow) are shown. IPMK fragments used for binding studies are shown in the schematic with
the number of the amino acid sequence.
(E) HA-mTOR or HA-raptor was cotransfected in HEK293T cells with wild-type or 1–60 deleted human IPMK (D1-60) constructs, followed by immunoprecipitation
with HA-antibodies and immunoblotting.
(F) Myc-wild-type mTOR, 1–1482 (N-ter) fragment, or 1328–2549 (C-ter) fragment was cotransfected in HEK293T cells with GFP or GFP-hIPMK-1-60, and myc-
immunoprecipitates were analyzed by immunoblotting.
(G) GST or GST-hIPMK-1-60 was incubated with mTOR purified from HEK293T cells.
(H) GST or GST-hIPMK was cotransfected in HEK293T cells with myc-raptor, followed by pull-down and immunoblotting.
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Inositol Polyphosphate Multikinase and mTORaffected by leucine availability (Figure 3A). Overexpression of
GFP-hIPMK-1-60 reduces the mTOR-raptor interaction by
60% in the presence but not the absence of leucine (Figure 3A).
By contrast, hIPMK-1-60 does not alter the association between
mTOR and rictor (Figure 3A).
We were concerned that hIPMK-1-60 might influence the
mTOR-raptor interaction secondary to effects on inositol phos-
phate metabolism. However, overexpression of GFP-hIPMK-
1-60 does not affect IP formation (Figure S1M).
The diminished mTOR-raptor binding elicited by hIPMK-1-60
has functional consequences. Thus, GFP-hIPMK-1-60 reduces
mTORC1 signaling by more than 60% (Figure 3B). Dominant-218 Cell Metabolism 13, 215–221, February 2, 2011 ª2011 Elsevier Innegative influences of hIPMK-1-60 peptide are supported by
in vitro experiments wherein the peptide prevents the formation
of the mTOR-raptor complex as assessed with or without cross-
linking (Figure 3C and Figure S4A) and markedly reduces
mTORC1 activity toward S6K (Figure 3C). The hIPMK-1-60
peptide does not influence mTORC2 activity whether assessed
in intact cells or in vitro (Figures S4B and S4C). The hIPMK-
1-182 and 182-416 fragments, which are responsible for
mTOR and raptor binding, also interfere with raptor binding to
mTOR and inhibit mTORC1 signaling (Figure S4D). The domi-
nant-negative actions of hIPMK-1-60 establish that IPMK-raptor
binding is involved in mTORC1 signaling.c.
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Figure 3. Human IPMK-1-60 Peptide Interferes with mTOR-Raptor
Binding and Amino Acid Signaling
(A) HEK293T cells transfected with GFP or GFP-hIPMK-1-60 were deprived of
serum and leucine for 1 hr and stimulated with leucine for 10min.mTORC1 and
mTORC2 were isolated in the presence of DSP, and the amount of mTOR was
analyzed.
(B) S6K phosphorylation and protein expression were analyzed by immuno-
blotting.
(C) The amount of myc-raptor bound in mTOR pull-down and in vitro mTORC1
activity were analyzed. mTOR immunopurified from leucine-treated HEK293T
cells and myc-raptor (100 nM) were coincubated with GST or GST-hIPMK-
1-60 (200 nM). Bars represent mean ± SD (n = 3 in A and C, n = 4 in B).
*p < 0.05; **p < 0.01.
Cell Metabolism
Inositol Polyphosphate Multikinase and mTOR
Cell MThe Amino Terminus of IPMK Stabilizes mTORC1
and Enhances Its Signaling
To further explore the importance of the amino terminus of IPMK
for mTOR signaling, we examined the effect of wild-type IPMK
on mTORC1 stability. Overexpression of wild-type mouse
IPMK in IPMK-depleted MEFs doubles mTOR-raptor binding
(Figure 4A) and amino acid-induced mTORC1 signaling by
more than 2-fold (Figures 1D and 4B). Mutant mouse IPMK
lacking amino acids 1–31, corresponding to hIPMK-1-60
(mIPMK-D1-31; see Figure 2D), fails to rescue mTOR-raptor
binding, mTORC1 signaling, and cell size defects in IPMK-
depleted MEFs (Figures 4A and 4B, and Figure S4E).
We wondered whether deleting the amino-terminal region of
mouse IPMK might cause major alterations in IPMK protein
folding or stability that would nonspecifically impair its activities
in rescuing mTOR signaling. Accordingly, we monitored inositol
phosphate metabolism in the IPMK-depleted MEFs overex-
pressing mIPMK-D1-31. We detect comparable amounts of
IP5 and IP6 (Figure S1K), which suggest that amino-terminal
deletion in mouse IPMK does not adversely affect the structural
and functional integrity of IPMK. Thus, the amino terminus of
IPMK is involved in stabilizing IPMK-mTOR binding and
enhancing downstream mTORC1 signaling.
DISCUSSION
Our study establishes IPMK as a physiologic determinant of
amino acid-induced mTORC1 signaling. Depletion of IPMK
reduces amino acid-stimulated mTOR activation by about
60%, comparable to the effects of depletion of major compo-
nents of the mTORC1 such as raptor (Kim et al., 2002). A mutant
IPMK that is devoid of catalytic activity stimulates mTOR
signaling as effectively as wild-type IPMK. Thus, regulation of
mTOR by IPMK is independent of IPMK’s catalytic activity.
We elucidated mechanisms whereby mammalian IPMK regu-
lates mTORC1 signaling. In MEFs, IPMK depletion selectively
disrupts mTOR-raptor, but not mTOR-rictor or mTOR-mLST8
interactions. IPMK’s stabilization of mTORC1 is dependent
upon the amino terminus of IPMK, which is present only in the
mammalian form of the enzyme. Overexpression of hIPMK-
1-60 selectively disrupts the mTOR-raptor interaction in the
presence of leucine and thereby dominant-negatively impairs
amino acid-induced mTORC1 signaling. Mutant mouse IPMK
lacking amino acids 1–31 fails to maintain mTOR-raptor binding
and activation of mTORC1 in response to amino acids. Thus, our
findings show that mammalian IPMK is a physiologic mTOR
cofactor involved inmaintaining the binding ofmTORwith raptor,
thereby influencing the activation of mTORC1 by nutrient amino
acids (Figure 4C). As hIPMK-1-60 peptide does not alter
mTORC1 stability under the leucine-deprived condition and
IPMK depletion does not fully abolish the mTOR-raptor binding,
we presume that other factors act together with IPMK.
Sabatini and associates proposed that mLST8, which occurs
in both mTORC1 and mTORC2, maintains the integrity of
mTORC2 (Guertin et al., 2006). In MEFs null for mLST8, interac-
tions of mTOR-rictor, but not mTOR-raptor, are lost, leading to
depressed mTORC2 signaling. IPMK also associates with
mTORC2, indicating that it can participate in the mTORC2
complex, and the decreased mTORC2 signaling toward Aktetabolism 13, 215–221, February 2, 2011 ª2011 Elsevier Inc. 219
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Figure 4. The Amino Terminus of IPMK Is Involved in mTOR-Raptor
Binding and Amino Acid Signaling
(A) In the presence of DSP, raptor immunoprecipitates were isolated from
IPMK-depleted MEFs stably expressing vector (Vec), wild-type (WT), or the
deletion mutant IPMK (D1-31) followed by immunoblotting.
(B) S6K phosphorylation and protein expression were analyzed by immuno-
blotting. Bars represent mean ± SD (n = 3). *p < 0.05; **p < 0.01.
(C) A model depicting regulation of mTORC1 signaling by IPMK in response to
amino acids. In the absence of amino acids, IPMK binds with high affinity to
mTORC1, the N-terminal portion of IPMK interacting with mTOR and the C
terminus with raptor. Amino acid stimulation transforms the complex into
a low-affinity state, whereupon the complex translocates to the lysosomal
surface. The active Rag/Regulator complex associates with raptor, and active
GTP-Rheb binds to mTOR, thereby enhancing mTOR activity (Sancak et al.,
2010). In the absence of IPMK the mTOR-raptor complex dissociates, at least
partially. Amino acid treatment still enhances raptor binding to the active Rag/
Regulator complex, but GTP-Rheb fails to bind/activate mTOR.
Cell Metabolism
Inositol Polyphosphate Multikinase and mTORSer473 phosphorylation in IPMK-depleted MEFs implies a func-
tional role for IPMK.
The regulation ofmTORsignalingby IPMK implies an important
role in cellular protein synthesis that is critical for life. Thusgenetic
deletion of mTOR (Gangloff et al., 2004; Murakami et al., 2004;
Guertin et al., 2006) or raptor (Guertin et al., 2006) leads to embry-
onic lethality at embryonic day 5.5–6.5 (E5.5–6.6) due to growth
and proliferation defects. IPMK knockout mice also die early in220 Cell Metabolism 13, 215–221, February 2, 2011 ª2011 Elsevier Indevelopment at around E9.5 due to severe growth and morpho-
logical defects, resembling the phenotype of mTOR or raptor
knockoutmice (Frederick et al., 2005). This similarity is consistent
with a role of IPMK in regulating mTORC1 function.
Obese patients frequently display increased plasma levels of
amino acids (Um et al., 2006; Dann et al., 2007), which parallels
reduced insulin sensitivity (Krebs, 2005). Nutrient amino acid
overload leads to hyperactivated mTORC1 signaling and insulin
resistance (Tremblay et al., 2005). Due to its role in protein
synthesis and growth, mTOR has been a major target for the
development of anticancer drugs. Interestingly, obesity is a risk
factor for many cancers (Calle and Kaaks, 2004), and anti-
diabetic drugs such as metformin, which activates AMP-kinase
and thereby inhibits mTORC1 signaling, inhibit cancer cell
growth and metabolism (Dowling et al., 2007). Accordingly,
drugs that impair IPMK-mediated regulation of the mTORC1
stability and function may be useful in treating obesity, diabetes,
and cancer.
EXPERIMENTAL PROCEDURES
Generation of Inducible Floxed IPMK Mice
Floxed IPMK mice were generated at Ozgene. A loxP site was inserted
between exons 5 and 6. Floxed IPMK mice were mated with knockin
C57BL/6 mice (Jackson Laboratory) carrying the tamoxifen-inducible, Cre-
ERT2 driven by a PGK promoter. Details are available in the Supplemental
Experimental Procedures.
MEFs
MEFs were immortalized by transfecting a SV40 large T-antigen plasmid.
Depletion of IPMK in MEFs was achieved by adding 4-hydroxytamoxifen
(1 mM) for 48 hr. Ethanol-treated MEFs were used for control.
Deprivation and Stimulation of Leucine, Arginine, and Total
Amino Acids
HEK293T cells or MEFs were rinsed with PBS and incubated in leucine-defi-
cient DMEM, arginine-deficient DMEM, or amino acids-deficient glucose
(4500 mg/L)-containing Krebs buffer (20 mM HEPES [pH 7.4], 118 mM NaCl,
4.6 mM KCl, 1 mMMgCl4, 12 mM NaHCO3, 0.5 mM CaCl2, 0.2% [w/v] bovine
serum albumin) for 1 hr. Cells were stimulated by leucine (400 mM), arginine
(400 mM), and amino acids mixture (13). Lysis, immunoprecipitations,
immunoblotting, and materials are available in the Supplemental Experimental
Procedures.
Crosslinking Assay and mTOR Kinase Assay
Assays were performed as previously described (Sancak et al., 2007, 2008).
Statistical Analysis
Data were analyzed by paired Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
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